Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
suraxavir marboxil
- Development stage
- Phase 3
- Lead developer
- Jiangxi Qingfeng Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Suraxavir marboxil (GP681) is an orally administered small molecule antiviral prodrug developed for the treatment and prophylaxis of influenza A and B. It is converted in vivo to its active metabolite, GP1707D07, which selectively inhibits the cap-dependent endonuclease (CEN) within the polymerase acidic (PA) subunit of the viral RNA polymerase complex. By blocking this "cap-snatching" mechanism, the drug prevents viral mRNA synthesis and replication. Developed by Qingfeng Pharmaceutical Group in collaboration with researchers from Capital Medical University, suraxavir marboxil has been approved for marketing by the National Medical Products Administration (NMPA) in China. It is typically administered as a single 40 mg dose and has demonstrated efficacy in shortening the time to alleviation of symptoms and reducing viral load in patients with acute uncomplicated influenza.
- Brand names
- Isuda
- Other names
- GP1707D07GP-1707D07GP 1707D07
02
Targets
CEN (Influenza A virus (2009 H1N1) polymerase acidic protein (PA) endonuclease)
Beyond the preview
Go deeper on suraxavir marboxil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on suraxavir marboxil.